Latest News
-
Sunday - November 10, 2019
Climate FieldView™ Partnership with CLAAS Brings Bayer Data Science to More Farms:
Global agreement supports FieldView expansion in Europe and other regions » more
-
Thursday - November 7, 2019
NOT FOR DISTRIBUTION IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN
Bayer refinances 1.75 billion euro hybrid bond
New issue of two tranches with a non-call period of 5.5 and 8 years combined with a tender offer for Bayer’s existing hybrid bond » more
-
Thursday - November 7, 2019
Bayer invests USD 50 Million in eGenesis Series B financing round
Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation » more
-
Monday - November 4, 2019
Bayer completes sale of Dr. Scholl’s™ brand to Yellow Wood Partners » more
-
Monday - November 4, 2019
Youth leaders take on the fight to feed a hungry planet
3-day Youth Ag Summit kicks off in Brasilia, Brazil on 4 November 2019 / One hundred young change-makers, representing 45 countries, gather to turn their ideas for food security into reality » more
-
Wednesday - October 30, 2019
Bayer AG Third Quarter 2019 Results and News Conference Call » more
-
Wednesday - October 30, 2019
Third quarter of 2019
Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health
Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases sales – earnings decline due to one-time income in prior year / Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings / Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year / Core earnings per share up by 6.4 percent to 1.16 euros / Group outlook confirmed and aligned to continuing operations » more
-
Tuesday - October 22, 2019
2019 World Para Athletics Championships in Dubai
Large Number of Bayer athletes competing in German team
2019 World Championships taking place in Dubai from November 7-15 / 10 out of 34 athletes from Bayer club compete for Germany / Bayer committed to supporting disabled sports » more
-
Monday - October 21, 2019
Bayer at the Annual Biocontrol Industry Meeting 2019:
“Biologicals by Bayer”, leading innovation for organic crop protection solutions » more
-
Wednesday - October 16, 2019
Bayer Animal Health and VLPbio sign global collaboration agreement
Bayer Animal Health to strengthen its technology portfolio for biological products » more
-
Monday - October 14, 2019
Not intended for U.S. and UK Media
U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE » more
-
Monday - October 14, 2019
Neptra® receives positive CVMP opinion for launch in Europe
Bayer's Neptra® ear drops solution for dogs treats susceptible strains of common pathogens found in canine otitis externa. » more
-
Thursday - October 10, 2019
Bayer inks deals with eleven startups under G4A Digital Health Partnerships program
Eleven healthcare startup companies to be supported by Bayer’s “G4ADigital Health Partnerships program” to drive forward innovative digital health solutions for patients / Includes financial funding, commercial partnerships in areas of cardiovascular health, oncology, ophthalmology, pulmonology, radiology, digital therapeutics » more
-
Thursday - October 10, 2019
Bayer launches LifeHub UK focused on Artificial Intelligence to optimize data-driven drug discovery and disease diagnosis
Collaborations with external partners will drive development of AI-enabled radiology to enhance patient outcomes / LifeHub UK is the newest member of Bayer’s network of LifeHubs designed to plug into the global innovation ecosystems to solve challenges in health and nutrition » more
-
Tuesday - October 1, 2019
Future of Farming Dialogue 2019 » more
-
Tuesday - October 1, 2019
Ertharin Cousin to become member of Bayer AG Supervisory Board
International expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of September » more
-
Tuesday - October 1, 2019
New company supported by over USD 55 million in committed funding from Bayer:
Bayer and Arvinas unveil targeted protein degradation joint venture, Oerth Bio
Oerth Bio to utilize Arvinas’ PROTAC® technology to develop innovative new agricultural products to improve crop yields / John Dombrosky announced as CEO of Oerth Bio / Transaction had been formally closed on July 15, 2019 » more
-
Tuesday - October 1, 2019
Future of Farming Dialogue hosted by Bayer:
Bayer committed to shaping a more sustainable food system
Agriculture is part of the solution for climate change / Investing more than 25 billion euros in Crop Science R&D over the next 10 years / Leading Digital Farming platform FieldView on 90 million paid acres this year » more
-
Monday - September 30, 2019
Bayer appoints Ingo Elfering Crop Science CIO and Head of Digital Transformation » more
-
Saturday - September 28, 2019
Not intended for U.S. and UK Media - European Society for Medical Oncology (ESMO) Congress 2019
Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer
79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years(1) / Largest dataset with longest follow-up of any TRK inhibitor illustrates favorable safety profile across ages and tumor types(1) » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Thursday, February 27, 2020
Financial News Conference on the Full Year 2019 Results
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV